Navigation Links
Eisai Announces Change in U.S. Submission Schedule for E7389 New Drug Application
Date:1/31/2008

cell lung cancer, prostate cancer and sarcoma.

E7389 is a novel compound developed by Eisai as a new potential anti- cancer agent that suppresses the growth of microtubule which is involved in various cellular processes in the body, such as cell division. E7389 is a synthetic analog of halichondrin B, a naturally-occurring compound which was first isolated from a type of marine sponge in 1992.

Eisai has a strong commitment to the development of new oncology medicines to address the unmet medical needs of patients with cancer. Currently, seven other Eisai oncology compounds are in clinical development, in addition to E7389.

About Eisai Co., Ltd.

Eisai Co., Ltd. is a research-based human health care (hhc) company that discovers, develops and markets products throughout the world. Eisai focuses its efforts in three therapeutic areas: neurology, gastrointestinal disorders and oncology/critical care. Through a global network of research facilities, manufacturing sites and marketing affiliates, Eisai actively participates in all aspects of the worldwide healthcare system.

About Eisai Corporation of North America

Eisai Corporation of North America is a wholly-owned subsidiary of Eisai Co., Ltd. and supports the activities of its operating companies in North America. These operating companies include: Eisai Research Institute of Boston, Inc., a discovery operation with strong organic chemistry capabilities; Morphotek, Inc., a biopharmaceutical company specializing in the development of therapeutic monoclonal antibodies; Eisai Medical Research Inc., a clinical development group; Eisai Inc., a commercial operation with manufacturing and marketing/sales functions; MGI PHARMA, INC., an R&D and commercial operation with manufacturing and marketing/sales functions; and Eisai Machinery U.S.A., which markets and maintains pharmaceutical manufacturing machinery.

*Accelerated Approval under Subpart H:

One of the programs within
'/>"/>

SOURCE Eisai Corporation of North America
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. TorreyPines Therapeutics and Eisai Co., Ltd. Extend Genetics Discovery Collaboration for Alzheimers Disease
2. U.S. District Court Decision About Eisais Legal Action Over Aricept ODT(R) ANDA Filing
3. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
4. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
5. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
6. BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.
7. Carrington Announces Nasdaq Communication; Prepares for Shares to Be Quoted on the OTC Bulletin Board and Pink Sheets
8. China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results
9. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
10. Advanced Life Sciences Announces Receipt of Nasdaq Staff Letter
11. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/29/2014)... TORONTO , Sept. 29, 2014 /PRNewswire/ - SQI ... company that develops and commercializes proprietary technologies and products ... appointment of Peter Winkley to Chairman of ... Ricks .  Mr. Ricks will continue to serve as ... provide leadership to the Company.  "We ...
(Date:9/29/2014)... CIRENCESTER, England , September 29, 2014 /PRNewswire/ ... tighter margins and greater competition to transform network ... brand   ProLabs , ... infrastructure products, announced today the findings of their ... Optical Communications (ECOC) with top optical communications professionals ...
(Date:9/29/2014)... ZIONA, Israel , September 29, ... stage company developing novel immunomodulators for severe infections, today ... ( BARDA ) has awarded Atox Bio with a ... for the development of AB103 to treat Necrotizing Soft ... and public health threats that end in sepsis. ...
(Date:9/29/2014)... , Sept. 29, 2014 CytRx ... research and development company specializing in oncology, today ... (FDA) has granted multiple Orphan Drug Designations for ... indications: glioblastoma multiforme (GBM), small cell lung cancer ... of the widely-used chemotherapeutic agent, doxorubicin. ...
Breaking Biology Technology:SQI Diagnostics Announces New Chairman of Board of Directors 2End of an Era: OEM Dominance - Could it be a Thing of the Past? 2Atox Bio Awarded Contract Worth up to $24 Million for the Development of AB103 by the Biomedical Advanced Research and Development Authority (BARDA) 2CytRx Receives Multiple FDA Orphan Drug Designations for Aldoxorubicin for the Treatment of Glioblastoma, Small Cell Lung Cancer and Ovarian Cancer 2CytRx Receives Multiple FDA Orphan Drug Designations for Aldoxorubicin for the Treatment of Glioblastoma, Small Cell Lung Cancer and Ovarian Cancer 3CytRx Receives Multiple FDA Orphan Drug Designations for Aldoxorubicin for the Treatment of Glioblastoma, Small Cell Lung Cancer and Ovarian Cancer 4CytRx Receives Multiple FDA Orphan Drug Designations for Aldoxorubicin for the Treatment of Glioblastoma, Small Cell Lung Cancer and Ovarian Cancer 5
... , LANSING, Mich., June 18 Fortune Magazine has ... in its annual list of the "40 best stocks to retire ... 40 list in 2002, stating: "We wanted to assemble a diversified, ... that could soar when the market did but also hold steady ...
... June 18 Environmental Tectonics Corporation,s (OTC Bulletin Board: ... the sale of an additional BARA-MED(R)XD monoplace hyperbaric oxygen ... The state-of-the-art monoplace chamber is among the first ... Oklahoma. , , Hyperbaric chambers are used ...
... FRANCISCO, June 18 Burrill & Company, a San ... Venture Capital, Private Equity, Merchant Banking and Media, is ... firm as Managing Director, Merchant Banking. Shawn will assist ... and capital raising transactions. In addition, Shawn will make ...
Cached Biology Technology:Neogen Named to Fortune's List of 40 Stocks 'To Retire On' 2Environmental Tectonics Corporation Announces Additional Hyperbaric Monoplace Chamber Sale to St. John Wound Center 2Environmental Tectonics Corporation Announces Additional Hyperbaric Monoplace Chamber Sale to St. John Wound Center 3Environmental Tectonics Corporation Announces Additional Hyperbaric Monoplace Chamber Sale to St. John Wound Center 4Shawn Cross Joins Burrill Merchant Banking 2Shawn Cross Joins Burrill Merchant Banking 3
(Date:9/29/2014)... A species of gut bacteria called Clostridium ramosum , ... weight. The work is published this week in mBio ... Microbiology. , A research team from the German Institute ... human gut bacteria including C. ramosum gained weight ... C. ramosum were less obese even when consuming ...
(Date:9/29/2014)... September 29: Between 1970 and 2010 populations of ... globe dropped 52 percent, says the 2014 Living ... (WWF). This biodiversity loss occurs disproportionately in low-income ... high-income countries. , In addition to the precipitous ... to other warning signs about the overall health ...
(Date:9/29/2014)... with children at home should use ventilation when cooking ... are recommending, after a new study showed an association ... and chronic bronchitis. , "In homes where a gas ... and wheezing is higher than in homes where a ... an associate professor in the College of Public Health ...
Breaking Biology News(10 mins):Gut bacteria promote obesity in mice 2Half of global wildlife lost, says new WWF report 2Childhood asthma linked to lack of ventilation for gas stoves, OSU study shows 2Childhood asthma linked to lack of ventilation for gas stoves, OSU study shows 3
... University of Alberta have pinpointed a genetic marker for sporadic ... in Caucasians., Researchers have identified many genetic markers for familial ... for 80 per cent of all cases. Sambasivarao Damaraju, a ... researcher at the Cross Cancer Institute, worked with his team ...
... a novel method of analyzing genetic variations in families, ... genetic variations affecting related biochemical processes may team up ... findings, reported May 28 in Translational Psychiatry , ... and schizophrenia, and may lead to a genetic test ...
... Osteoporosis Foundation,s key regional meeting in Hong Kong ... enriching scientific programme of direct relevance to your ... experts from around the world. http://www.iofbonehealth.org/hongkong-2013/ ... Plenary sessions devoted to epidemiology, ...
Cached Biology News:U of A medical researchers ID genetic marker for sporadic breast cancer 2Family studies suggest rare genetic mutations team up to cause schizophrenia 2
... Disposable. Virgin, optically clear polystyrene ... and alphanumeric coordinates for cell counting. ... number is a new product number, ... number. If showing no availability yet, ...
... The Luminex 100 IS System is a compact ... that integrates lasers, optics, fluidics, a controller, advanced ... This powerful, compact lab analysis system includes the ... Also, it has a DMF file at the ...
... gradient system is ideal for routine binary separations. ... sensitive Adept CE 4201 UV-Visible variable wavelength detector. ... provided by the two highly accurate and ... 4100 solvent delivery pumps., Chromatograms may be plotted ...
... Hep G2 cells were cultured in Minimum Essential ... at the log phase of growth. In ... forms, cells were fixed in acetone-methanol. The ... adhesive coated slide, with each wells surface specifically ...
Biology Products: